Dosing of the first patient represents the commencement of the trial’s Phase I safety run-in portion. Credit: jarmoluk from Pixabay.

Cellenkos has dosed the first patient in a Phase I/Ib trial assessing its cell therapy CK0803 to treat amyotrophic lateral sclerosis (ALS).

CK0803 is a neurotrophic, allogeneic, umbilical cord blood-derived T regulatory cell therapy that specially targets central nervous system.

Related Company Profiles

View all

It has been developed by using Cellenkos’ proprietary CRANE technology.

The dosing represents the commencement of the trial’s Phase I safety run-in portion that includes six patients.

This portion will be followed by a Phase Ib randomised, double blind, placebo control trial of the cell therapy in further 60 ALS patients.

See Also:

During the regulatory T cells for amyotrophic lateral sclerosis (REGALS) trial, patients will receive four weekly infusions followed by five infusions per month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The multicentre study is led by Columbia University Eleanor and Lou Gehrig ALS Center director and Neurology associate professor as well as principal investigator Neil Shneider.

Columbia University is the key site of the trial.

The Phase I trial’s primary objective is to establish the safety and tolerability of various CK0803 doses in the enrolled patients.

The Phase Ib trial will offer preliminary efficacy findings employing the primary endpoint of combined assessment of function and survival (CAFS) that ranks clinical results of patients on the basis of survival time and change in the ALS Functional Rating Scale-Revised score.

Its secondary endpoint is longitudinal measurement of neurofilament light chain levels in serum and cerebrospinal fluid.

Cellenkos chief operating officer Tara Sadeghi said: “The initiation of this study of CK0803 is an important achievement that brings us closer to delivering a potential new treatment which may have a life-changing impact for ALS.

“ALS is a devastating disease with no cure, and we believe that CK0803 has the potential to provide a much-needed treatment option for patients.”